Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

NCT02342704 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

111

Enrollment

INDUSTRY

Sponsor class

Stopped Business Decision

Conditions

Relapsing-Remitting Multiple Sclerosis

Interventions

DRUG: natalizumab
DRUG: fingolimod

Sponsor

Biogen